CKD Bio Corp. (063160.KS)
KRW 22500.0
(-1.96%)
KRW 22500.0
(-1.96%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 160.35 Billion KRW | 2.76% |
| 2022 | 156.04 Billion KRW | 9.7% |
| 2021 | 142.23 Billion KRW | 14.16% |
| 2020 | 124.59 Billion KRW | -9.17% |
| 2019 | 137.18 Billion KRW | 10.18% |
| 2018 | 124.51 Billion KRW | 5.35% |
| 2017 | 118.18 Billion KRW | 4.58% |
| 2016 | 113.01 Billion KRW | 5.93% |
| 2015 | 106.69 Billion KRW | 0.28% |
| 2014 | 106.38 Billion KRW | 6.0% |
| 2013 | 100.37 Billion KRW | -11.77% |
| 2012 | 113.75 Billion KRW | 2.92% |
| 2011 | 110.52 Billion KRW | -9.08% |
| 2010 | 121.56 Billion KRW | 14.09% |
| 2009 | 106.55 Billion KRW | 27.77% |
| 2008 | 83.39 Billion KRW | 25.57% |
| 2007 | 66.4 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 45.53 Billion KRW | 28.88% |
| 2024 Q2 | 50.91 Billion KRW | 11.81% |
| 2024 Q3 | 43.88 Billion KRW | -13.81% |
| 2023 Q2 | 38.98 Billion KRW | -10.79% |
| 2023 Q4 | 35.33 Billion KRW | -16.56% |
| 2023 FY | 160.35 Billion KRW | 2.76% |
| 2023 Q1 | 43.69 Billion KRW | 25.15% |
| 2023 Q3 | 42.34 Billion KRW | 8.63% |
| 2022 Q3 | 37.59 Billion KRW | 2.5% |
| 2022 Q2 | 36.67 Billion KRW | -21.74% |
| 2022 Q1 | 46.86 Billion KRW | 40.87% |
| 2022 FY | 156.04 Billion KRW | 9.7% |
| 2022 Q4 | 34.91 Billion KRW | -7.12% |
| 2021 Q2 | 37.48 Billion KRW | 11.78% |
| 2021 Q1 | 33.53 Billion KRW | 25.18% |
| 2021 Q3 | 37.95 Billion KRW | 1.26% |
| 2021 Q4 | 33.26 Billion KRW | -12.35% |
| 2021 FY | 142.23 Billion KRW | 14.16% |
| 2020 Q1 | 30.39 Billion KRW | -19.94% |
| 2020 Q3 | 32.67 Billion KRW | -5.93% |
| 2020 Q4 | 26.78 Billion KRW | -18.03% |
| 2020 FY | 124.59 Billion KRW | -9.17% |
| 2020 Q2 | 34.74 Billion KRW | 14.31% |
| 2019 Q1 | 31.31 Billion KRW | 3.32% |
| 2019 Q3 | 34.94 Billion KRW | 6.02% |
| 2019 Q4 | 37.96 Billion KRW | 8.62% |
| 2019 FY | 137.18 Billion KRW | 10.18% |
| 2019 Q2 | 32.96 Billion KRW | 5.28% |
| 2018 Q2 | 30.87 Billion KRW | 0.31% |
| 2018 Q3 | 32.55 Billion KRW | 5.44% |
| 2018 FY | 124.51 Billion KRW | 5.35% |
| 2018 Q1 | 30.77 Billion KRW | 7.1% |
| 2018 Q4 | 30.3 Billion KRW | -6.9% |
| 2017 Q1 | 30 Billion KRW | 10.54% |
| 2017 FY | 118.18 Billion KRW | 4.58% |
| 2017 Q4 | 28.73 Billion KRW | -0.28% |
| 2017 Q3 | 28.81 Billion KRW | -5.9% |
| 2017 Q2 | 30.62 Billion KRW | 2.07% |
| 2016 FY | 113.01 Billion KRW | 5.93% |
| 2016 Q4 | 27.14 Billion KRW | -7.66% |
| 2016 Q3 | 29.39 Billion KRW | 6.23% |
| 2016 Q2 | 27.66 Billion KRW | -3.95% |
| 2016 Q1 | 28.8 Billion KRW | 6.31% |
| 2015 FY | 106.69 Billion KRW | 0.28% |
| 2015 Q2 | 28.34 Billion KRW | 16.75% |
| 2015 Q3 | 26.96 Billion KRW | -4.87% |
| 2015 Q1 | 24.27 Billion KRW | -2.84% |
| 2015 Q4 | 27.09 Billion KRW | 0.48% |
| 2014 Q3 | 26.18 Billion KRW | -2.17% |
| 2014 Q2 | 26.76 Billion KRW | -5.94% |
| 2014 Q1 | 28.45 Billion KRW | 22.42% |
| 2014 Q4 | 24.98 Billion KRW | -4.56% |
| 2014 FY | 106.38 Billion KRW | 6.0% |
| 2013 FY | 100.37 Billion KRW | -11.77% |
| 2013 Q2 | 26.05 Billion KRW | -3.93% |
| 2013 Q3 | 23.95 Billion KRW | -8.05% |
| 2013 Q1 | 27.11 Billion KRW | -10.54% |
| 2013 Q4 | 23.24 Billion KRW | -2.97% |
| 2012 FY | 113.75 Billion KRW | 2.92% |
| 2012 Q4 | 30.31 Billion KRW | 0.17% |
| 2012 Q3 | 30.26 Billion KRW | 11.22% |
| 2012 Q2 | 27.21 Billion KRW | 4.79% |
| 2012 Q1 | 25.96 Billion KRW | -7.94% |
| 2011 Q1 | 32.63 Billion KRW | -5.02% |
| 2011 FY | 110.52 Billion KRW | -9.08% |
| 2011 Q4 | 28.2 Billion KRW | 13.73% |
| 2011 Q3 | 24.8 Billion KRW | -0.35% |
| 2011 Q2 | 24.88 Billion KRW | -23.73% |
| 2010 Q3 | 29.56 Billion KRW | 3.8% |
| 2010 FY | 121.56 Billion KRW | 14.09% |
| 2010 Q2 | 28.47 Billion KRW | -2.39% |
| 2010 Q1 | 29.17 Billion KRW | 9.8% |
| 2010 Q4 | 34.35 Billion KRW | 16.22% |
| 2009 Q4 | 26.57 Billion KRW | 7.05% |
| 2009 FY | 106.55 Billion KRW | 27.77% |
| 2009 Q2 | 26.23 Billion KRW | -9.31% |
| 2009 Q1 | 28.92 Billion KRW | 23.36% |
| 2009 Q3 | 24.82 Billion KRW | -5.38% |
| 2008 Q3 | 22.3 Billion KRW | 21.16% |
| 2008 Q4 | 23.44 Billion KRW | 5.1% |
| 2008 Q1 | 19.22 Billion KRW | 10.15% |
| 2008 FY | 83.39 Billion KRW | 25.57% |
| 2008 Q2 | 18.41 Billion KRW | -4.21% |
| 2007 FY | 66.4 Billion KRW | 0.0% |
| 2007 Q3 | 16.7 Billion KRW | 14.04% |
| 2007 Q1 | 17.6 Billion KRW | 0.0% |
| 2007 Q2 | 14.65 Billion KRW | -16.77% |
| 2007 Q4 | 17.45 Billion KRW | 4.45% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -16.867% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 85.835% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | 74.884% |
| HANDOK Inc. | 522.74 Billion KRW | 69.325% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -18.453% |
| Yuhan Corporation | 1858.98 Billion KRW | 91.374% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | 75.85% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -208.638% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 89.244% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -18.859% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 56.724% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -80.998% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | 5.434% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | 28.56% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -16.867% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -105.44% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -6.144% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -83.546% |
| JW Holdings Corporation | 928.07 Billion KRW | 82.722% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | 73.308% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 90.395% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 78.578% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | 19.915% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | 11.291% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | 18.331% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 77.925% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -16.867% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 89.412% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 88.341% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 78.578% |
| Yuhan Corporation | 1858.98 Billion KRW | 91.374% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 79.823% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | 31.736% |
| Suheung Co., Ltd. | 594.56 Billion KRW | 73.03% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 78.578% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | 45.109% |
| Korea United Pharm Inc. | 278.94 Billion KRW | 42.514% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | 69.57% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | 55.594% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | 30.401% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | 19.915% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 81.774% |
| Boryung Corporation | 859.62 Billion KRW | 81.346% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -27.337% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 56.724% |
| JW Lifescience Corporation | 206.86 Billion KRW | 22.483% |